Bristol-Myers Squibb Co. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Bristol-Myers Squibb Co. (NYSE:BMY) will unveil its latest earnings on Thursday, January 26, 2012. Bristol-Myers Squibb is a global company that develops, manufactures, and sells pharmaceutical products.

Bristol-Myers Squibb Co. Earnings Preview Cheat Sheet.

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 55 cents per share, a rise of 17% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 56 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 55 cents during the last month. For the year, analysts are projecting net income of $2.30 per share, a rise of 6.5% from last year.

Past Earnings Performance: Last quarter, the company reported profit of 61 cents per share versus a mean estimate of net income of. The company has beaten estimates for the past three quarters.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: Analysts are projecting a rise of 7.6% in revenue from the year-earlier quarter to $5.5 billion.

Analyst Ratings: Analysts are bullish on Bristol-Myers Squibb as 11 analysts rate it as a buy, two rate it as a sell and nine rate it as a hold.

A Look Back: In the third quarter, profit rose 2.1% to $969 million (56 cents a share) from $949 million (55 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 11.4% to $5.34 billion from $4.8 billion.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 14% in the second quarter from the year earlier, climbed 4.2% in the first quarter from the year-ago quarter and 74.9% in the fourth quarter of the last fiscal year.

The increase in profit in the third quarter came after net income fell in the previous quarter. In the second quarter, net income fell 2.7%.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Sanofi-Aventis SA (NYSE:SNY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), and AstraZeneca plc (NYSE:AZN).

Stock Price Performance: During November 21, 2011 to January 20, 2012, the stock price had risen $2.53 (8.4%) from $30.12 to $32.65. The stock price saw one of its best stretches over the last year between September 9, 2011 and September 20, 2011 when shares rose for eight-straight days, rising 8% (+$2.28) over that span. It saw one of its worst periods between December 29, 2011 and January 5, 2012 when shares fell for five-straight days, falling 2.2% (-77 cents) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.